Silexion Therapeutics Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$14MTTM through 30 Jun 2026
Free Cash Flow -$12.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -8,590.6% |
| Net Margin | -8,540.6% |
Returns
-59.4%ROA
Balance Sheet Health
Debt / Equity6.84x
Current Ratio1.00x
Net Debt-$860Knet cash position
Cash & Equivalents$2.2M
Quality Metrics
Altman Z-Score-31.00
Piotroski F-Score2 / 9
Earnings-Beat Rate100.0%
Multi-Year Trend
Diluted EPSFY2025: $8.96
Dividend
No dividend
Capital Allocation
R&D Spend$9.1M
Capex Intensity6.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| RNA Interference Therapeutics | $32K | View detailsSilexion is focused on initiating its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, with regulatory approvals secured in Israel and applications submitted in Germany. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.